Dr. Janetka’s Research Awards
March 1st, 2022 – Jim Janetka, PhD, Professor in Biochemistry and Molecular Biophysics and David Sibley, Professor in Molecular Microbiology received a new five-year grant R01 award from the National Institute of Allergy and Infectious Diseases (NIAID) of the NIH totaling 3.9 million dollars for their research entitled “Optimizing CDPK1 inhibitors for chronic toxoplasmosis”.
September 30th, 2021 – Jim Janetka, PhD, Professor of Biochemistry and Molecular Biophysics, Makedonka Mitreva, Professor of Medicine and Genetics, and Sara Lustigman, Professor and Head, Laboratory of Molecular Parasitology Member, Lindsley F. Kimball Research Institute, New York Blood Center have received a new multi-PI R01 award from the National Institutes of Health, National Eye Institute entitled “Integrative approach for accelerating filarial worm drug discovery to treat river blindness”.
March 18th, 2021 – Jim Janetka, PhD, Professor of Biochemistry and Molecular Biophysics, Makedonka Mitreva, Professor of Medicine and Genetics, and Raffi Aroian, Professor of Molecular Medicine at the University of Massachusetts Medical School have received a new multi-PI R01 award from the National Institutes of Health, National Institute of Allergy and Infectious Diseases entitled “Development of small molecule inhibitors of metabolic enzymes as broad-spectrum anthelmintic drugs”.
March 17th, 2021 – Jim Janetka, PhD, Professor of Biochemistry and Molecular Biophysics, along with Scott Hultgren, Helen L. Stoever Professor of Molecular Microbiology, Michael Caparon, Professor of Molecular Microbiology, Peng Yuan, Associate Professor of Cell Biology and Physiology, and Ali Ellebedy, Associate Professor of Pathology and Immunology received a five-year U19 Research Program–Cooperative Agreement Award from the National Institutes of Health, National Institute of Allergy and Infectious Diseases entitled “Innovative Strategies to Combat Antibiotic-resistant Infections”. Dr. Janetka is leader of the project scientific core named “Rational Design and Synthesis of Small Molecule Inhibitors Targeting Unique Pathogenic Mechanisms in Gram- and Gram+ Bacteria Important in UTI”.
September 16th, 2019 – Jim Janetka, PhD, Associate Professor of Biochemistry and Molecular Biophysics, and Co-Founder of ProteXase Therapeutics, Inc., along with Lidija Klampfer, PhD, Co-Founder and Chief Scientific Officer of ProteXase Therapeutics, Inc., received a one-year SBIR grant award from the National Cancer Institute for their research entitled “Inhibitors of pro-HGF activation overcome resistance to anti-EGFR therapy”.
June 14th, 2019 – Jim Janetka, PhD, Associate Professor of Biochemistry and Molecular Biophysics, received a two-year Siteman Investment Program (SIP) award from the Siteman Cancer Center and Foundation for Barnes Jewish-Hospital for his research entitled “The role of pericellular serine proteases in tumor progression and resistance to anticancer therapy”.
April 9th, 2018 – Jim Janetka, PhD, Associate Professor of Biochemistry and Molecular Biophysics, and Co-Founder of ProteXase Therapeutics, Inc., along with Lidija Klampfer, PhD, Co-Founder and Chief Scientific Officer of ProteXase Therapeutics, Inc., received a one-year SBIR grant award from the National Cancer Institute for their research entitled “Targeting Hepatocyte Growth Factor with Protease Inhibitors in Lung Cancer”.
October 2nd, 2017 – Jim Janetka, PhD, Associate Professor of Biochemistry and Molecular Biophysics and Chemistry Adjunct received a two year, Career Catalyst Research (CCR) Competitive Renewal Grant Program award from Susan G. Komen for the Cure for his research entitled “Multifunctional inhibitors of MET/RON signaling and cross-talk with EGFR/HER2”. The work is focused on developing new drugs to treat breast cancer by dual targeting of the tumor and its microenvironment.
January 30th, 2017 – Jim Janetka, PhD, Associate Professor of Biochemistry and Molecular Biophysics and Chemistry Adjunct, along with Scott Hultgren, PhD, Helen L. Stoever Professor of Molecular Microbiology received and a four year grant award from the National Institute of Diabetes and Digestive and Kidney Diseases for his research entitled “Small Molecule Bacterial Lectin Antagonists for UTI Treatment and Prevention”.
September 27th, 2016 – Jim Janetka, PhD, Associate Professor, Department of Biochemistry and Molecular Biophysics, received a new two year grant award from the Alvin J. Siteman Cancer Research Fund for his research entitled “Inhibitors of growth factor activation as new adjunct chemotherapy for cancer”.
More information here: “Siteman fund grants $300,000 for unique approaches to fighting cancer”